Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.

Assetmark Inc. cut its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 14.6% in the undefine

Andra AP fonden cut its stake in Bristol Myers Squibb Company (NYSE: BMY) by 51.2% in the first quar

Bessemer Group Inc. boosted its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 19.6% in the

AlTi Global Inc. reduced its position in Bristol Myers Squibb Company (NYSE: BMY) by 92.0% in the un

Bristol Myers Squibb adopts NVIDIA DGX SuperPOD to train next-gen AI models and accelerate drug disc

Bristol Myers Squibb said on Monday it is buying the latest-generation computing system from chip co

PRINCETON, N.J.--(BUSINESS WIRE)---- $bmy--Bristol Myers Squibb to Build the Most Powerful AI Factor

Dimensional Fund Advisors LP boosted its position in shares of Bristol Myers Squibb Company (NYSE: B

Allspring Global Investments Holdings LLC grew its stake in shares of Bristol Myers Squibb Company (

Bristol Myers Squibb (BMY) reached $60.48 at the closing of the latest trading day, reflecting a +2.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right co

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it

BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in ad

Approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with es

Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect

The U.S. Food and Drug Administration (FDA) on Monday accepted the new drug application for Bristol

FDA accepts Bristol Myers Squibb's mezigdomide NDA for relapsed multiple myeloma, with a PDUFA d

Application based on results from SUCCESSOR-2 trial showing oral CELMoD mezigdomide in combination w

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts Bristol Myers Squibb's New Drug App

B of A Securities analyst Tim Anderson maintains Bristol-Myers Squibb (NYSE:BMY) with a Buy and l

Retiring on dividends remains achievable for late starters by building a high-yield, quality portfol

They may not remain cheap for too much longer.

AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic

Cantor Fitzgerald analyst Carter Gould reiterates Bristol-Myers Squibb (NYSE:BMY) with a Neutral

Bristol Myers Squibb is generating more than enough earnings to cover its dividend right now. Howeve

The Nasdaq 100 has tripled since 2020, but 10 mega-caps still trade below pre-Covid levels. Who'

Bristol Myers Squibb expands AI efforts through Anthropic and Tempus partnerships as shares edge hig

In times of market turbulence, investors turn to dividend-yielding stocks. Benzinga provides real-ti

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t

The US Supreme Court turned away appeals from six pharmaceutical companies seeking to topple the Med

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook

Investors turn to dividend-yielding stocks during market turbulence. Benzinga's database offers

Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9%

Here's a look at this week's earnings calendar, featuring over 100 S&P 500 members.

Investors stepped back into beaten-down tech names Friday, with the Nasdaq 100 rising 0.6% by midday

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue

A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp.

  On Thursday, 369 companies hit new 52-week lows.

  On Wednesday, 311 stocks hit new 52-week lows.